Clinical effect of CAG regimen on patients with acute myeloid leukemia and myelodysplastic syndrome

VernacularTitle:CAG预激方案治疗急性髓系白血病及骨髓增生异常综合征
Author: Hong LIANG ; Haijun ZHAO
Publication Type:Journal Article
Keywords: Leukemia,myeloid,acute; Myelodysplastic syndromes; Priming chemotherapy
From: Journal of Leukemia & Lymphoma 2010;19(10):607-609
CountryChina
Language:Chinese
Abstract: Objective To explore the efficacy and side effect of CAG (G-CSF, aclarubicin and cytarabine) priming chemotherapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods 54 patients with AML at diagnosis and relapse or MDS were'enrolled for the initial treatment with CAG regimen. Patients who have achieved complete remission (CR) were treated with various regimens. Results The total effective rate was 72.2 %, complete remission rate was 48.1% and partial remission rate was 24.1%. The incidence of granulocyte deficiency was 40.7 %(22/54). The severe infection rate was 24.1%(13/54). One case died of function damage in liver. The study includes 36 patients below 60 years, 18 patients above 60 years, and overall effective cases are 28 (77.8 %), 11 (61.1%),respectively. There was significant difference (P ＜0.05). Conclusion CAG regimen is effective and well tolerated in remission for AML and MDS-RAEB.